BRAINSWAY LTD/S (NASDAQ:BWAY) Downgraded by Zacks Investment Research to Sell

BRAINSWAY LTD/S (NASDAQ:BWAY) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Monday, Zacks.com reports.

According to Zacks, “BrainsWay Ltd. is a commercial stage medical device company. It is focused on the development and sale of non-invasive neuromodulation products using the Company’s proprietary Deep Transcranial Magnetic Stimulation technology for the treatment of major depressive disorder and obsessive-compulsive disorder. BrainsWay Ltd. is based in Jerusalem, Israel. “

BRAINSWAY LTD/S stock traded up $0.24 on Monday, reaching $9.24. The company’s stock had a trading volume of 1,610 shares, compared to its average volume of 11,346. The company’s fifty day moving average is $9.95. BRAINSWAY LTD/S has a twelve month low of $8.00 and a twelve month high of $12.39.

BRAINSWAY LTD/S (NASDAQ:BWAY) last posted its quarterly earnings data on Monday, August 26th. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.06). The business had revenue of $5.70 million during the quarter, compared to the consensus estimate of $5.30 million. As a group, equities analysts forecast that BRAINSWAY LTD/S will post -0.52 EPS for the current year.

Institutional investors have recently bought and sold shares of the business. Victory Capital Management Inc. acquired a new position in BRAINSWAY LTD/S in the second quarter worth $157,000. Noked Capital LTD acquired a new position in BRAINSWAY LTD/S in the second quarter worth $572,000. ARK Investment Management LLC acquired a new position in BRAINSWAY LTD/S in the second quarter worth $863,000. Finally, Delek Group Ltd. acquired a new position in BRAINSWAY LTD/S in the second quarter worth $3,176,000. 10.84% of the stock is currently owned by institutional investors.

BRAINSWAY LTD/S Company Profile

Brainsway Ltd. engages in the development and provision of technology solutions for non-invasive treatment of brain disorders in Israel and internationally. It offers deep transcranial magnetic stimulation systems for treating various conditions, including autism, Alzheimer's disease, bipolar disorders, chronic pains, depressive disorders, Parkinson's diseases, schizophrenia, smoking cessation, post-traumatic stress disorders, multiple sclerosis, obsessive compulsive disorders, and stroke rehabilitation.

See Also: Tariff

Get a free copy of the Zacks research report on BRAINSWAY LTD/S (BWAY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for BRAINSWAY LTD/S (NASDAQ:BWAY)

Receive News & Ratings for BRAINSWAY LTD/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BRAINSWAY LTD/S and related companies with MarketBeat.com's FREE daily email newsletter.